

Zotefoams plc

Issue of Equity

15 April 2025 - Zotefoams plc (LSE: ZTF) announces that it has conditionally agreed to allot and issue 400,000 new ordinary shares of five pence each in the capital of the Company ("Ordinary Shares") on 22 April 2025, (the "New Shares").

The New Shares, which will rank pari passu with the existing Ordinary Shares in issue, will be allotted and issued to the Zotefoams plc 2007 Employee Benefit Trust (the "EBT") at the par value of five pence each in order to satisfy future exercises of awards under the Group's share incentive schemes.

The EBT will thereafter hold a total of 519,557 Ordinary Shares, representing approximately 1.05 percent of the enlarged issued share capital of the Company.

Applications have been made to the Financial Conduct Authority (the "FCA") for the admission of the New Shares to the equity shares (commercial companies) category of the Official List of the FCA and to London Stock Exchange plc for admission to trading of the New Shares on its main market for listed securities (together, "Admission"). Admission is expected to become effective at 8.00 a.m. on 22 April 2025.

The allotment and issue of the New Shares are conditional upon Admission becoming effective.

Following Admission, the Company will have 49,246,234 Ordinary Shares in issue. There are no Ordinary Shares held in treasury. Therefore, following Admission the total number of voting rights in the Company will be 49,246,234 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their voting rights interest, or a change to that interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Zotefoams plc

+44 (0) 208 664 1600

Ronan Cox, Group CEO

Gary McGrath, Group CFO

IFC Advisory (Financial PR & IR)

+44 (0) 203 934 6630

Graham Herring

Zach Cohen

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE® polyolefin and ZOTEK® high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT® advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce® mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacturer), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA, Stilling, Denmark (microcellular foam technology) and Jiangsu Province, China (T-FIT).

www.zotefoams.com

AZOTE®, ZOTEK®, ReZorce® and T-FIT® are registered trademarks of Zotefoams plc

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEGPUGWCUPAGBC